AI/Machine Learning Pre-Conference Focus Day
Tuesday, March 19, 2024

8:00 am Registration & Morning Coffee

8:55 am Chair’s Opening Remarks

Leveraging AI to Classify IBD Subtypes for Improved Disease Management

9:00 am Wearable and Connected Technologies: Harnessing AI & Machine Learning in the Management of IBD

  • Robert Hirten Clinical Director, The Hasso Plattner Institute of Digital Heath at Mount Sinai; Associate Professor of Medicine & Artificial..., Icahn School of Medicine at Mount Sinai


  • Discuss how non-invasive wearable devices and the physiological data they collect can be used in the management of health and disease
  • Discuss how we can leverage the data collected from novel technologies through AI/ML to monitor IBD activity
  • Discuss how wearable and connected technologies can non-invasively monitor for drug response

9:30 am Panel Discussion: Using AI-Enhanced Phenotyping to Provide Novel Understanding of IBD Heterogeneity


  • To what extent will AI reshape the classification of IBD subtypes?
  • What insights does classify IBD subtypes provide into disease heterogeneity?
  • Delving into AI-enhanced phenotyping for tailoring bespoke treatment options 

10:30 am Morning Networking Break

Optimizing Data Handling to Improve Patient Selection for Better Personalized IBD Treatment Options

11:30 am Practical Considerations of Application in IBD to Improve Patient Care


  • Real-world applications of AI in personalized medicine for IBD, including how AI-driven tools could be used to diagnose and monitor patient progress
  • How can we integrate AI effectively and ethically into clinical practice to ensure regulatory considerations, data privacy, and strategies during a successful implementation?

12:00 pm AI for multi-omics analysis and discovery of biomarkers of disease progression in Crohn’s Disease

  • Andres Hurtado-Lorenzo Senior Vice President, Translational Research & IBD Ventures, Crohn’s & Colitis Foundation


  • Discuss the implementation of machine learning for identification of prognostic biomarkers of progression to complicated disease behaviour using transcriptomics and proteomics data sets.
  • Discuss whether AI-based immunoprofiling could support the identification of disease specific autoantibodies for patient subtyping.

12:30 pm Lunch & Networking Break

Harnessing AI/ML to Predict Patient Progression for Improved Clinical Outcomes for IBD Patients

1:30 pm Roundtable Discussion: Enhancing Clinical Trial Design to Effectively Catalyse Clinical Studies & Accelerate IBD Drug Development

  • Mera Telley Vice President, Genetics & Precision Immunology, Alumis


  • How can utilise AI to improve patient selection and eligibility screening for novel therapeutics?
  • How can we use the wealth of clinical data for protocol optimization within the context of clinical design?
  • Can we use AI/ML for predictive analytics, identifying potential complications or negative reactions in early stages of clinical trials?
  • Could we implement real-time patient monitoring to identify trends or anomalies that may require immediate attention?
  • Are modalities required for companion diagnostics sufficient to implement into clinical trials?

2:30 pm Catalyzing Discovery: Unleashing the Power of AI in Protein Engineering for Innovative Anti-Inflammatory Therapeutics

  • James Bowman Director - Protein Engineering,Nvestigator & Discovery Investigator, AI Proteins


  • How AI can be used to generate de novo miniprotein for better medicines
  • A case study – the power of AI in drug discovery

3:00 pm Navigating AI in Clinical Trials: Unraveling Challenges in Histology-based Disease Assessment for IBD Patients

  • Dawid Rymarczyk Lead Data Scientist & Computer Vision Specialist, Ardigen


  • Annotation Granularity: Can we rely on the AI model trained without detailed annotations of tissue pathologies?
  • Batch Effects on AI Models: Do batch effects negatively affect the AI reasoning process and how to prevent them?
  • Matching Expert Accuracy: Do clinical conclusions about the disease state derived from the AI model, matching histology experts' accuracy, align with clinicians' assessments?

3:10 pm Afternoon & Networking Break

Wielding Machine Learning to Optimize Drug Response Rate & Efficacy for Enhanced Therapeutic Potential

4:00 pm Roundtable Discussion: Navigating the Ethical and Regulatory Landscape of AI in Precision Medicine for IBD

  • Nicole Desch Associate Director, GI Drug Discovery, Takeda


  • Explore methods to empower patients with a comprehensive understanding of AI applications in their healthcare decisions
  • Discuss potential biases in AI algorithms used for IBD classification and their impact on diverse patient populations
  • Discuss the importance of transparently explaining AI-driven decisions to both clinicians and patients, fostering trust and acceptance

4:30 pm Panel Discussion: Synergizing Precision Medicine and Computational Sciences: Leveraging AI, Wearables, and Advanced Simulation Tools


  • Integrating advanced simulation tools, machine learning, and AI techniques to enhance precision medicine in IBD
  • Cross-disciplinary collaboration between industry and healthcare for accelerated therapeutic development
  • Leveraging computational sciences to model complex processes and optimize treatment strategies

5:00 pm Chair’s Closing Remarks & End of Pre-Conference Focus Day